Table 2.
siRNAs in cancer therapeutics
| Target | Drug name | Cancer | Phase | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| PKN3 | Atu027 | Carcinoma, Pancreatic Ductal | I | NCT00938574 |
| PKN3 | Atu027 | Carcinoma, Pancreatic Ductal | I/II | NCT01808638 |
| KRAS | siG12D LODER | Pancreatic ductal adenocarcinoma, pancreatic cancer | I | NCT01188785 |
| KRAS | siG12D LODER | Pancreatic ductal adenocarcinoma, pancreatic cancer | II | NCT01676259 |
| KrasG12D mutation | Mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA | Pancreatic cancer | I | NCT03608631 |
| PLK1 | TKM-080301 | Adrenal cortical carcinoma, neuroendocrine tumor, hepatocellular carcinoma | I/II | NCT01262235 |
| PLK1 | TKM-080301 | Adrenal cortical carcinoma, neuroendocrine tumor, hepatocellular carcinoma | I | NCT01437007 |
| PLK1 | TKM-080301 | Adrenal cortical carcinoma, neuroendocrine tumor, hepatocellular carcinoma | I/II | NCT02191878 |
| AR V7 variant | SXL01 | Metastatic castration-resistant prostate cancer (CRPC) | I | NCT02866916 |
| EphA2 | EPHARNA | Advanced Malignant Solid Neoplasm | I | NCT01591356 |
| BCL2L12 | NU-0129 | Gliosarcoma, recurrent Glioblastoma | I | NCT03020017 |
| VEGF and KSP | ALN-VSP02 | Solid tumors | I | NCT01158079 |
| RRM2 | CALAA-01 | Cancer, solid tumor | I Terminated | NCT00689065 |
| MYC | DCR-MYC | Hepatocellular Carcinoma, Solid Tumors; Multiple Myeloma, or Lymphoma | I Terminated | NCT02314052 |
| MYC | DCR-MYC | Hepatocellular Carcinoma, Solid Tumors; Multiple Myeloma, or Lymphoma | Ib/II Terminated | NCT02110563 |